Progressive House Democrats press for a more aggressive remedy than arbitration to reduce drug prices; FDA permits the sale of a new cigarette alternative; use of methamphetamine surges in some parts of the United States.
Yesterday, the Congressional Progressive Caucus urged Energy and Commerice Committee Chairman Frank Pallone Jr, D-NJ, and House Ways and Means Committee Chairman Richard Neal, D-MA, to support a bill allowing the government to strip drug companies of their monopolies if they refuse to set reasonable prices for expensive drugs, The Hill reported. Progressive House Democrats opposed a competing proposal that suggested an outside arbitrator should be brought in to help determine prices the government would pay for high-priced drugs, claiming a system of arbitration would be too weak. While lawmakers said the chairmen listened and expressed consideration for multiple ideas, they did not offer any of their own plans.
The FDA will allow the tobacco giant, Phillip Morris, to sell a new cigarette alternative, named IQOS, which heats sticks of tobacco without burning them and creates a nicotine-infused aerosol, according to Associated Press. The FDA has not yet determined whether to allow the device to be marketed as a healthier alternative to cigarettes. Regulators stressed that IQOS is neither safe nor “FDA approved.” Studies have shown that the product produced fewer toxic byproducts than traditional combustible cigarettes.
Use of methamphetamine has been surging in parts of the United States, NPR reported. As many as 70% of local law enforcement agencies in the West and Midwest have said meth is their biggest drug threat. However, these officials said policymakers in the nation’s capital have done little to address their concerns, considering the threat posed by the opioid epidemic has been receiving the majority of attention and funding. As a result, addiction treatment providers and first responders have been left struggling to handle the declining situation.
Urticaria Diagnosis Challenged by Overlapping Pruritic Skin Conditions
April 23rd 2025Urticaria is complicated to diagnose by its symptomatic overlap with other skin conditions and the frequent misclassification in literature of distinct pathologies like vasculitic urticaria and bullous pemphigus.
Read More
New Research Challenges Assumptions About Hospital-Physician Integration, Medicare Patient Mix
April 22nd 2025On this episode of Managed Care Cast, Brady Post, PhD, lead author of a study published in the April 2025 issue of The American Journal of Managed Care®, challenges the claim that hospital-employed physicians serve a more complex patient mix.
Listen
Personalized Care Key as Tirzepatide Use Expands Rapidly
April 15th 2025Using commercial insurance claims data and the US launch of tirzepatide as their dividing point, John Ostrominski, MD, Harvard Medical School, and his team studied trends in the use of both glucose-lowering and weight-lowering medications, comparing outcomes between adults with and without type 2 diabetes.
Listen
ACOs’ Focus on Rooting Out Fraud Aligns With CMS Vision Under Oz
April 23rd 2025Accountable care organizations (ACOs) are increasingly playing the role of data sleuths as they identify and report trends of anomalous billing in hopes of salvaging their shared savings. This mission dovetails with that of CMS, which under the new administration plans to prioritize rooting out fraud, waste, and abuse.
Read More